{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:24:57Z","timestamp":1793975097159,"version":"4.8.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism Open"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.metop.2026.100497","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:22:10Z","timestamp":1789453330000},"page":"100497","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Real-world treatment-transition pathways and dosing patterns of insulin degludec\/liraglutide in Chinese adults with type 2 diabetes"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6958-7562","authenticated-orcid":false,"given":"Jie","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0664-4424","authenticated-orcid":false,"given":"Fuli","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6863-1798","authenticated-orcid":false,"given":"Lixin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metop.2026.100497_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International diabetes Federation diabetes atlas","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.metop.2026.100497_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.metop.2026.100497_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108078","article-title":"Diabetes and global ageing among adults aged 65\u201399 years: findings from the international diabetes Federation diabetes atlas","volume":"162","author":"Sinclair","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.metop.2026.100497_bib5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/nyas.12098","article-title":"Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States","volume":"1281","author":"Ma","year":"2013","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.metop.2026.100497_bib6","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S2213-8587(19)30425-5","article-title":"Association of insulin resistance and beta-cell dysfunction with incident diabetes among adults in China: a nationwide, population-based, prospective cohort study","volume":"8","author":"Wang","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metop.2026.100497_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3062","article-title":"Blood glucose profiles in East Asian and Caucasian injection-naive patients with type 2 diabetes inadequately controlled on oral medication: a pooled analysis","volume":"34","author":"Zhang","year":"2018","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.metop.2026.100497_bib8","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s00125-012-2827-3","article-title":"Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis","volume":"56","author":"Kim","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.metop.2026.100497_bib9","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.diabres.2015.12.004","article-title":"Efficacy and tolerability of exenatide twice daily and exenatide once weekly in Asian versus white patients with type 2 diabetes mellitus: a pooled analysis","volume":"114","author":"Sheu","year":"2016","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.metop.2026.100497_bib10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1586\/17446651.2016.1113129","article-title":"Insulin degludec\/liraglutide (IDegLira) for the treatment of type 2 diabetes","volume":"11","author":"Gough","year":"2016","journal-title":"Expert Rev Endocrinol Metabol"},{"key":"10.1016\/j.metop.2026.100497_bib11","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.pcd.2015.12.005","article-title":"IDegLira: redefining insulin optimisation using a single injection in patients with type 2 diabetes","volume":"10","author":"Hughes","year":"2016","journal-title":"Prim Care Diabetes"},{"key":"10.1016\/j.metop.2026.100497_bib12","article-title":"Xultophy (insulin degludec\/liraglutide) summary of product characteristics","author":"Novo Nordisk","year":"2021","journal-title":"Bagsvaerd, Denmark: Novo Nordisk A\/S"},{"key":"10.1016\/j.metop.2026.100497_bib13","first-page":"1","article-title":"Xultophy (insulin degludec\/liraglutide) summary of product characteristics","author":"Novo Nordisk","year":"2017","journal-title":"Bagsvaerd, Denmark: Novo Nordisk A\/S"},{"key":"10.1016\/j.metop.2026.100497_bib14","series-title":"Xultophy (Insulin degludec\/liraglutide) prescribing information","first-page":"1048","author":"Novo","year":"2016"},{"key":"10.1016\/j.metop.2026.100497_bib16","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.2337\/dc14-0785","article-title":"Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira)","volume":"37","author":"Buse","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metop.2026.100497_bib15","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2337\/dc17-1114","article-title":"Efficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: the DUAL VII randomized clinical trial","volume":"41","author":"Billings","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metop.2026.100497_bib17","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S2213-8587(14)70174-3","volume":"2","author":"Gough","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metop.2026.100497_bib18","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/jama.2016.1252","article-title":"Effect of insulin glargine Up-titration vs insulin degludec\/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: the DUAL V randomized clinical trial","volume":"315","author":"Lingvay","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.metop.2026.100497_bib19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s13300-016-0218-3","article-title":"The efficacy of IDegLira (Insulin degludec\/liraglutide combination) in adults with type 2 diabetes inadequately controlled with a GLP-1 receptor agonist and oral therapy: DUAL III randomized clinical trial","volume":"8","author":"Linjawi","year":"2017","journal-title":"Diabetes Therapy"},{"key":"10.1016\/j.metop.2026.100497_bib20","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1111\/dom.13666","article-title":"Superior efficacy of insulin degludec\/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: a randomized clinical trial in people with uncontrolled type 2 diabetes","volume":"21","author":"Philis-Tsimikas","year":"2019","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.metop.2026.100497_bib21","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/dme.13256","article-title":"Safety and efficacy of insulin degludec\/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naive people with Type 2 diabetes: the DUAL IV trial","volume":"34","author":"Rodbard","year":"2017","journal-title":"Diabet Med"},{"key":"10.1016\/j.metop.2026.100497_bib22","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1111\/dom.13856","article-title":"Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naive Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trial","volume":"21","author":"Kaku","year":"2019","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.metop.2026.100497_bib34","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/1753-0407.13286","article-title":"DUAL I China: improved glycemic control with IDegLira versus its individual components in a randomized trial with Chinese participants with type 2 diabetes uncontrolled on oral antidiabetic drugs","volume":"14","author":"Wang","year":"2022","journal-title":"J Diabetes"},{"key":"10.1016\/j.metop.2026.100497_bib23","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/dom.12539","article-title":"Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial","volume":"17","author":"Ahmann","year":"2015","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.metop.2026.100497_bib24","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.2337\/dc14-0876","article-title":"Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes","volume":"37","author":"Diamant","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metop.2026.100497_bib27","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/dom.13182","article-title":"Use and effectiveness of a fixed-ratio combination of insulin degludec\/liraglutide (IDegLira) in a real-world population with type 2 diabetes: results from a european, multicentre, retrospective chart review study","volume":"20","author":"Price","year":"2018","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.metop.2026.100497_bib28","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12902-022-01139-8","article-title":"Real-world effectiveness of IDegLira compared with intensified conventional insulin therapy in adults with type 2 diabetes: a retrospective cohort study","volume":"22","author":"Szepkuti","year":"2022","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.metop.2026.100497_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.endmts.2020.100057","article-title":"IRWIS (IDegLira real world Indian study): a real-world observational study for use of IDegLira in Indian patients","volume":"1","author":"Gangopadhyay","year":"2020","journal-title":"Endocr Metabol Sci"},{"issue":"4","key":"10.1016\/j.metop.2026.100497_bib42","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s13300-026-01852-w","article-title":"Improved glycaemic control with IDegLira in Chinese adults with type 2 diabetes in real-world settings: a retrospective, database cohort study","volume":"17","author":"Wang","year":"2026","journal-title":"Diabetes Ther"},{"issue":"5","key":"10.1016\/j.metop.2026.100497_bib43","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1111\/dom.15486","article-title":"IDegLira for the real-world treatment of type 2 diabetes in Italy. Final results from the REX observational study","volume":"26","author":"Fadini","year":"2024","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.metop.2026.100497_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2025.112119","article-title":"The impact of IDegLira in treatment simplification in older adults with type 2 diabetes mellitus already on insulin therapy: the STOP study","volume":"223","author":"De Fano","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.metop.2026.100497_bib41","series-title":"Report of a WHO consultation","article-title":"Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus","year":"1999"},{"issue":"12","key":"10.1016\/j.metop.2026.100497_bib40","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1111\/dom.14522","article-title":"DUAL II China: superior HbA1c reductions and weight loss with insulin degludec\/liraglutide (IDegLira) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin","volume":"23","author":"Pei","year":"2021","journal-title":"Diabetes Obes Metabol"}],"container-title":["Metabolism Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589936826000563?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589936826000563?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:29:32Z","timestamp":1793971772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589936826000563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":32,"alternative-id":["S2589936826000563"],"URL":"https:\/\/doi.org\/10.1016\/j.metop.2026.100497","relation":{},"ISSN":["2589-9368"],"issn-type":[{"value":"2589-9368","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world treatment-transition pathways and dosing patterns of insulin degludec\/liraglutide in Chinese adults with type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"Metabolism Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metop.2026.100497","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100497"}}